Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + trastuzumab + vinorelbine neoadjuvant therapy for HER2-positive breast cancer with poor response to prior TCHP
ChiCTR2100047650Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib, trastuzumab and vinorelbine in breast cancer, sponsored by Chongqing University Cancer Hospital. Primary endpoint: Pathological complete response rate. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100047650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047650.